Recent advances in managing triple-negative breast cancers.
Triple-negative breast cancer (TNBC) has been recently recognized as an important subgroup of breast cancer with a distinct outcome and therapeutic approach compared with other breast cancer subgroups. Because TNBC is defined by the absence of a target (either hormone receptors or HER-2), conventional cytotoxic therapy is still the mainstay of treatment. This report focuses on the current state and recent advances in managing TNBC.
Bengala
Carmelo
C
Division of Medical Oncology, Department of Oncology, Hematology and Respiratory Diseases, University Hospital, University of Modena and Reggio Emilia Via del Pozzo, 71 - 41100, Modena Italy.